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5-Fluorouracil (5-FU) is a widely used drug in head and neck squamous cell carcinoma (HNSCC). In the anabolic pathway of
5-FU, the ﬁrst step in activation of the drug is phosphorylation of 5-FU by orotate phosphoribosyltransferase (OPRT), which
directly metabolizes 5-FU to 5-ﬂuorouridine monophosphate (FUMP) in the presence of 5-phosphoribosyl-1-pyrophosphate.
To date, OPRT expression in the tumors has been related to the clinical response or survival of cancer patients receiving 5-FU-
based chemotherapy. In this study, we examined whether OPRT expression correlates with the chemosensitivity to 5-FU and cell
proliferation in HNSCC. We constitutively expressed an OPRT cDNA in an HNSCC cell line. The eﬀects of OPRT expression on
in vitro cell growth and 5-FU cytotoxicity were examined. OPRT transfection increases the cytotoxicity of 5-FU without aﬀecting
cell proliferation of HNSCC cells in vitro. These results indicate that OPRT expression plays an important role in the sensitivity of
HNSCC to 5-FU chemotherapy.
1.Introduction
5-Fluorouracil (5-FU) has been used most frequently for
treating head and neck squamous cell carcinoma (HNSCC)
in a form of single agent or in combination with cisplatin
[1] and the drug of choice for systemic therapy in colorectal
cancer [2]. However, nowadays 5-FU resistance during the
course of treatment has become common, which is an
important cause of failure for cancer therapies [3].
It has been reported that response rate of 5-FU and
its derivatives are due to interindividual diﬀerence in the
enzyme activities for anabolism and catabolism. In the
anabolic pathway of 5-FU, the ﬁrst step in activation of the
drug is phosphorylation of 5-FU by orotate phosphoribo-
syltransferase (OPRT), which directly metabolizes 5-FU to
5-ﬂuorouridine monophosphate (FUMP) in the presence
of 5-phosphoribosyl-1-pyrophosphate [4]. This step is the
most important mechanism of 5-FU activation. To date,
OPRT expression in the tumors has been related to the
clinical response or survival of cancer patients receiving
5-FU-based chemotherapy [5, 6]. However, no study has
conﬁrmed directly whether the regulation of intratumoral
OPRT expression level aﬀects the eﬃcacy of 5-FU and the
cell activity in HNSCC. We therefore investigated whether
overexpression of the OPRT enhances sensitivity to 5-FU.
In this study, to assess the role of OPRT in the biological
regulation of HNSCC, we constitutively expressed the OPRT
complementaryDNA(cDNA)inHNSCCcellline. Theeﬀect
of OPRT on in vitro cell growth and 5-FU cytotoxicity was
examined.
2.MaterialsandMethods
2.1. Cell Line. The human head and neck squamous cell
carcinoma cell line, YCU-H, which was generously provided
by Dr. M. Tsukuda, was cultured in RPMI 1640 medium
and supplemented with 10% fetal bovine serum (FBS) and
penicillin/streptomycin 1000IU/mL (Invitrogen, Carlsbad,
CA, USA). Cells were maintained in a humidiﬁed incubator
at 37◦C under 5% CO2.2 Journal of Oncology
2.2.VectorConstructionandTransfection. Full-lengthhuman
OPRT cDNA (kindly provided by Taiho Pharmaceutical
Co. Ltd., Tokyo, Japan) that contained the entire coding
sequence was subcloned in its sense orientation into Eco
RI-Kpn I sites of the expression vector pTARGET. Human
YCU-H cells were stably transfected with the pTARGET-
OPRT plasmid and the pTARGET vector control plasmid
via liposome-mediated transfection using Lipofectamine
2000 (Invitrogen), according to the conditions described
by the supplier. Forty eight hours after transfection, trans-
duced cells were selected in complete medium containing
500μg/mL Geneticin (Invitrogen) for 2 to 3 weeks. After
selection, single independent clones were randomly isolated
using cloning rings, and each clone was plated separately.
2.3. Western Blot Analysis of Cultured Cells. Western blot
analyses were performed as reported previously [7, 8]t o
detect the OPRT expression in the YCU-H cell line. Total
cellular protein was extracted and quantiﬁed using the M-
Per Mammalian Protein Extracted Reagent and “Coomassie”
Protein Assay Reagent Kit (Pierce, Rockford, IL). Equal
amounts (10μg )o fc e l ll y s a t e sw e r es u b j e c t e dt oS D S -
polyacrylamide gel electrophoresis and transferred to a
n i t r o c e l l u l o s em e m b r a n e .T h em e m b r a n ew a sb l o c k e df o r
1h with 5% nonfat dry milk in PBS and then incubated
with the puriﬁed polyclonal antibody against OPRT (kindly
provided by Taiho Pharmaceutical Co. Ltd., Tokyo, Japan)
or an anti-β-actin antibody (Sigma Chemical Company, St.
Louis, MO, USA) for loading control for 1h at 37◦C. The
membranes were then incubated with the HRP-conjugated
goat anti-rabbit Ig G secondary antibody for 1h at room
temperature, followed by the detection with the enhanced
chemiluminescence (ECL) system (Amersham International,
Buckinghamshire, UK).
2.4. In Vitro Proliferation Assays. Transfected clone and
vector control clone cells (1 × 104 cells/dish) were seeded
onto 35 mm dishes in RPMI 1640 medium plus 10% FBS.
The number of the cells was counted every 48 hours for 8
subsequent days, in triplicate assays, using a Coulter Counter
(Beckman Coulter, Fullerton, CA, USA). The mean values
were used to generate growth curves.
2.5.DrugSensitivityAssay. Transfectedcellsandcontrolcells
were plated in 96-well plates at a density of 104 cells/well and
further incubated for 24h. The medium was then removed
and replaced with fresh medium containing 5-FU (kindly
provided by Kyowa Hakko Co. Ltd.) for another 48h. Then,
10μL sterile MTT dye (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide, 5mg/mL; Sigma) was added
to the culture medium to a ﬁnal concentration of 0.5mg/mL
and incubated at 37◦C for 2h. After that, the formazan
crystals were solubilized with 100μL of dimethylsulfoxide
(DMSO) for 10min. Spectrometric absorbance at 550nm
was measured with microplate reader. The IC50 value was
determinedbythedoseofdrugthatcaused50%cellviability.
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Figure 1: Western blot analysis indicating OPRT expression levels
in human head and neck squamous cell carcinoma YCU-H cells
transfected with OPRT cDNA. The OPRT protein level was
increased 35 times in the OPRT transfected clones H-OPRT in
comparison with the parental cell line, YCU-H cells.
2.6. Statistical Analysis. Statistical analyses were performed
using the Mann-Whitney U test. The Kaplan-Meier method
was used for analysis of survival data. The signiﬁcance of
diﬀerences of survival plots was analyzed by the log-rank
test. Diﬀerences with a P value <0.05 were considered to be
signiﬁcant.
3. Results
3.1. Transfection of OPRT cDNA in YCU-H Human Head and
Neck SCC Cell Line. Four independent clones were selected
after 2 to 3 weeks of growth in medium supplemented with
Geneticin (500μg/mL). Representative clone, H-OPRT, was
selected for use in subsequent experiments. The levels of
OPRToftheselectedcloneandYCU-Hcellsareillustratedin
Figure 1. The level of OPRT protein was increased 35 times
in the H-OPRT cells compared to control cells, respectively.
3.2. In Vitro Growth of the OPRT Overexpressing Cell Line.
When grown in 10% fetal bovine serum medium, the vector
control cell lines and OPRT transfected cell line showed
similar doubling times. There were no signiﬁcant diﬀerences
in in vitro growth between OPRT overexpressing clone and
control clones (Figure 2).
3.3. Correlation between the Level of OPRT Expression in
HNSCC Cells and Their Sensitivity to 5-FU. Cell cytotoxic
assays were performed using MTT assay to examine whether
the transfected OPRT cDNA increased 5-FU sensitivity in
the OPRT overexpressing cells. The increased sensitivity of
the OPRT transfected cells to 5-FU was observed in H-OPRT
cells. The 50% growth inhibitory (IC50)v a l u et o5 - F Ui nH -
OPRTcellswas11μM,whichwaslowerthanthoseofcontrol
cells (IC50: 150μM) (Figure 3).
4. Discussion
For decades, 5-FU and its derivatives such as 5 -DFUR and
tegafur have been used to treat cancer patients, and the
eﬀectiveness of 5-FU is well proven in HNSCC. However,
the presence of drug-resistant tumor cells, which occurs with
other chemotherapeutic agents as well, causes poor response
to 5-FU-based chemotherapy [3].Journal of Oncology 3
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Figure 2: In vitro growth curve of the OPRT transfectants. There
were no signiﬁcant diﬀerences in in vitro growth between OPRT
clone and control clones. :Y C U - H ,:p T A R G E T ,:H - O P R T .
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Figure 3: The cytotoxic eﬀect of 5-FU was measured by MTT assay.
IC50 valueswereestimatedfromtheregressionlineoflog-logitplots
of concentration versus growth inhibition rate. Twenty-four hours
after plating, the cells were exposed to 5-FU for 2 days. Each value
represents the mean of triplicate plates; bars, SD. :p T A R G E T ,:
H-OPRT.
To phosphorylate 5-FU into its nucleotides, the fol-
lowing 3 metabolic pathways have been reported: path-
way 1: phosphorylation to 5-ﬂuorouridine monophosphate
(FUMP) by OPRT; pathway 2: phosphorylation to 5-ﬂuo-
rodeoxyuridine (FdUR) by TP and a sequent conversion
to 5-ﬂuorodeoxyuridine-monophosphate (FdUMP) by thy-
midine kinase (TK); pathway 3: phosphorylation to 5-ﬂuor-
ouridine (FUR) by UP and a sequent conversion to FUMP
by uridine kinase (UK) [9, 10]. Thus, OPRT is one of the
main enzymes responsible for the phosphorylation of 5-FU
in human cancer cells. In addition, several clinical reports
have demonstrated a relationship between OPRT activity in
the tumors and clinical response of cancer patients receiving
5-FU-based chemotherapy [5, 6]. However, the role of OPRT
expression in HNSCC has not been established and, to the
best of our knowledge, there are no studies investigating the
relationship between the in vitro OPRT expression and 5-FU
cytotoxicity in HNSCC.
To directly conﬁrm whether the overexpression of OPRT
aﬀects the sensitivity to 5-FU and to review the role of
OPRT in HNSCC cells, we transfected OPRT cDNA in a
human HNSCC cell line, YCU-H. As a result, we found a
35-fold higher expression of the endogeneous OPRT protein
in OPRT transfected YCU-H cells. The present study also
demonstrated that the increased sensitivity to 5-FU was
observed in OPRT overexpressing cells. Inaba et al. reported
a signiﬁcantly low activity of OPRT in the 5-FU-resistant cell
line by measuring the enzyme activities in the human cancer
cell lines, [11]. Taomoto et al. also indicated that OPRT
overexpression plays an important role in the increased
sensitivity of gastric carcinomas to 5-FU chemotherapy [4].
The present result is compatible with those of the earlier
studies. These results, combined with other reports, strongly
suggest that overexpression of the OPRT in cancer cells
enhances the sensitivity to 5-FU treatment.
There were no signiﬁcant diﬀerences in the in vitro
growth between OPRT overexpressing cells and control cells
inthisstudy.TheseresultsshowthatoverexpressionofOPRT
protein is not linked to rapid tumor cell proliferation of
HNSCC cells. On the other hand, in bladder carcinoma, it
was reported that OPRT activity was upregulated compared
with the activity in normal bladder and that OPRT may
be of prognostic value [12]. Miyake et al. also reported
that OPRT may play a potential role in regulating the
malignant potential of pancreatic cancer [13]. Because the
regulation of OPRT expression and its involvement with
tumor proliferation remains unclear, we could not reach any
conclusion about the relationship between this enzyme and
tumor progression.
In conclusion, our data suggest that OPRT aﬀects the
chemotherapeuticeﬀectof5-FUinHNSCCcellsinvitro.The
present results strongly indicate that OPRT overexpression
plays an important role in the sensitivity of HNSCC to 5-FU
chemotherapy. Because the level of OPRT expression could
be used as a predictive indicator for 5-FU eﬃcacy against
HNSCC,theaccuratepredictionof5-FUeﬃcacymayhelpto
select patients for more intensive treatment including CDDP
based chemoradiotherapy.
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